204 related articles for article (PubMed ID: 31325233)
1. Ki67, CD105 and α-smooth muscle actin expression in disease progression model of oral submucous fibrosis.
Gadbail AR; Chaudhary MS; Sarode SC; Gondivkar SM; Belekar L; Mankar-Gadbail MP; Dande R; Tekade SA; Yuwanati MB; Patil S
J Investig Clin Dent; 2019 Nov; 10(4):e12443. PubMed ID: 31325233
[TBL] [Abstract][Full Text] [Related]
2. Ki67, CD105, and α-SMA Expression Supports Biological Distinctness of Oral Squamous Cell Carcinoma Arising in the Background of Oral Submucous Fibrosis.
Gadbail AR; Korde S; Chaudhary MS; Sarode SC; Gondivkar SM; Dande R; Tekade SA; Yuwanati M; Hande A; Patil S
Asian Pac J Cancer Prev; 2020 Jul; 21(7):2067-2074. PubMed ID: 32711434
[TBL] [Abstract][Full Text] [Related]
3. Ki67, CD105, and α-SMA expression supports the transformation relevant dysplastic features in the atrophic epithelium of oral submucous fibrosis.
Gadbail AR; Chaudhary M; Sarode SC; Gondivkar S; Tekade SA; Zade P; Hande A; Sarode GS; Patil S
PLoS One; 2018; 13(7):e0200171. PubMed ID: 30001387
[TBL] [Abstract][Full Text] [Related]
4. Ki67, CD105, and α-SMA expressions better relate the binary oral epithelial dysplasia grading system of World Health Organization.
Gadbail AR; Chaudhary MS; Sarode SC; Gawande M; Korde S; Tekade SA; Gondivkar S; Hande A; Maladhari R
J Oral Pathol Med; 2017 Nov; 46(10):921-927. PubMed ID: 28672080
[TBL] [Abstract][Full Text] [Related]
5. Comparison of myofibroblasts expression in oral squamous cell carcinoma, verrucous carcinoma, high risk epithelial dysplasia, low risk epithelial dysplasia and normal oral mucosa.
Chaudhary M; Gadbail AR; Vidhale G; Mankar Gadbail MP; Gondivkar SM; Gawande M; Patil S
Head Neck Pathol; 2012 Sep; 6(3):305-13. PubMed ID: 22392407
[TBL] [Abstract][Full Text] [Related]
6. Ki-67, CD105, and α-smooth muscle actin expression in oral squamous cell carcinoma corresponds with different forms of tobacco consumption habits.
Gadbail AR; Sarode SC; Chaudhary MS; Gondivkar SM; Tekade SA; Yuwanati M; Sarode GS; Hande A; Patil S
J Cancer Res Ther; 2022 Dec; 18(Supplement):S197-S204. PubMed ID: 36510964
[TBL] [Abstract][Full Text] [Related]
7. Molecular profiling of oral squamous cell carcinoma associated with oral submucous fibrosis.
Choudhari S; Masne S; Bhandare P; Dhumal S
J Cancer Res Ther; 2022; 18(1):55-65. PubMed ID: 35381762
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemical biomarkers in oral submucous fibrosis: A scoping review.
Kavitha L; Ranganathan K; Shyam S; Fathima JHS; Umesh W; Warnakulasuriya S
J Oral Pathol Med; 2022 Aug; 51(7):594-602. PubMed ID: 35102645
[TBL] [Abstract][Full Text] [Related]
9. Expression of Ki67 Biomarker in Oral Submucous Fibrosis with Clinico-Pathological Correlations: A Prospective Study.
Kamala KA; Kanetkar SR; Datkhile KD; Sankethguddad S
Asian Pac J Cancer Prev; 2022 Jan; 23(1):253-259. PubMed ID: 35092395
[TBL] [Abstract][Full Text] [Related]
10. Ki67 Labelling Index predicts clinical outcome and survival in oral squamous cell carcinoma.
Gadbail AR; Sarode SC; Chaudhary MS; Gondivkar SM; Tekade SA; Yuwanati M; Patil S
J Appl Oral Sci; 2021; 29():e20200751. PubMed ID: 33656066
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of stromal myofibroblasts in oral leukoplakia, oral submucous fibrosis, and oral squamous cell carcinoma--an immunohistochemical study.
Gupta K; Metgud R; Gupta J
J Cancer Res Ther; 2015; 11(4):893-8. PubMed ID: 26881537
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of stromal myofibroblasts in oral submucous fibrosis and its malignant transformation: An immunohistochemical study.
Liu Z; Hu W; Shan Z; Liu S; Yao Z; Quan H
J Cancer Res Ther; 2024 Apr; 20(2):706-711. PubMed ID: 38687943
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical detection of p53 and p63 in oral squamous cell carcinoma, oral leukoplakia, and oral submucous fibrosis.
Varun BR; Ranganathan K; Rao UK; Joshua E
J Investig Clin Dent; 2014 Aug; 5(3):214-9. PubMed ID: 23776093
[TBL] [Abstract][Full Text] [Related]
14. Differential expression of programmed death-1 and its ligand, programmed death ligand-1 in oral squamous cell carcinoma with and without oral submucous fibrosis.
Quan H; Liu S; Shan Z; Liu Z; Chen T; Hu Y; Yao Z; Fang L
Arch Oral Biol; 2020 Nov; 119():104916. PubMed ID: 32977151
[TBL] [Abstract][Full Text] [Related]
15. Significance of HIF-1α and CD105 in establishing oral squamous cell carcinoma associated with oral submucous fibrosis a distinct clinicopathological entity.
Hande AH; Chaudhary MS; Gadbail AR; Gawande MN; Patil SK; Zade PR; Sharma PN; Jaiswal SG; Sonone AM
J Cancer Res Ther; 2022; 18(1):33-41. PubMed ID: 35381759
[TBL] [Abstract][Full Text] [Related]
16. The Role of Increased Connective Tissue Growth Factor in the Pathogenesis of Oral Submucous Fibrosis and its Malignant Transformation-An Immunohistochemical Study.
Shah AM; Jain K; Desai RS; Bansal S; Shirsat P; Prasad P; Bodhankar K
Head Neck Pathol; 2021 Sep; 15(3):817-830. PubMed ID: 33544386
[TBL] [Abstract][Full Text] [Related]
17. Comparison of microvessel density using CD34 and CD105 in oral submucous fibrosis and its correlation with clinicopathological features: An immunohistochemical study.
Pammar C; Nayak RS; Kotrashetti VS; Hosmani J
J Cancer Res Ther; 2018; 14(5):983-988. PubMed ID: 30197335
[TBL] [Abstract][Full Text] [Related]
18. Identification of a combined biomarker for malignant transformation in oral submucous fibrosis.
Bazarsad S; Zhang X; Kim KY; Illeperuma R; Jayasinghe RD; Tilakaratne WM; Kim J
J Oral Pathol Med; 2017 Jul; 46(6):431-438. PubMed ID: 27497264
[TBL] [Abstract][Full Text] [Related]
19. Oral squamous cell carcinoma in the background of oral submucous fibrosis is a distinct clinicopathological entity with better prognosis.
Gadbail AR; Chaudhary M; Gawande M; Hande A; Sarode S; Tekade SA; Korde S; Zade P; Bhowate R; Borle R; Patil S
J Oral Pathol Med; 2017 Jul; 46(6):448-453. PubMed ID: 28129456
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical study of p21 and Bcl-2 in leukoplakia, oral submucous fibrosis and oral squamous cell carcinoma.
Sutariya RV; Manjunatha BS
J Exp Ther Oncol; 2016 Nov; 11(4):285-292. PubMed ID: 27849339
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
